Abstract:Background Our previous study revealed that administration of syngeneic female BALB/c mice with excessive self activated lymphocyte-derived DNA (ALD-DNA) could induce systemic lupus erythematosus (SLE) disease, indicating that overload of self-DNA might exceed normal clearance ability and comprise the major source of autoantigens in lupus mice. Serum amyloid P component (SAP), an acute-phase serum protein with binding reactivity to DNA in mice, was proved to promote the clearance of free DNA and prevent mice against self-antigen induced autoimmune response. It is reasonable to hypothesize that SAP treatment might contribute to alleviation of SLE disease, whereas its role in ALD-DNA-induced lupus nephritis is not fully understood. Methodology/Principal Findings The ratios of SAP to DNA significantly decreased and were negatively correlated with the titers of anti-dsDNA antibodies in ALD-DNA-induced lupus mice, indicating SAP was relatively insufficient in lupus mice. Herein a pcDNA3-SAP plasmid (pSAP) was genetically constructed and intramuscularly injected into BALB/c mice. It was found that SAP protein purified from the serum of pSAP-treated mice bound efficiently to ALD-DNA and inhibited ALD-DNA-mediated innate immune response in vitro. Treatment of ALD-DNA-induced lupus mice with pSAP in the early stage of SLE disease with the onset of proteinuria reversed lupus nephritis via decreasing anti-dsDNA autoantibody production and immune complex (IC) deposition. Further administration of pSAP in the late stage of SLE disease that had established lupus nephritis alleviated proteinuria and ameliorated lupus nephritis. This therapeutic effect of SAP was not only attributable to the decreased levels of anti-dsDNA autoantibodies, but also associated with the decreased infiltration of lymphocytes and the reduced production of inflammatory markers. Conclusion/Significance These results suggest that SAP administration could effectively alleviated lupus nephritis via modulating anti-dsDNA antibody production and the inflammation followed IC deposition, and SAP-based intervening strategy may provide new approaches for treating SLE disease.

Development of an IL-17A DNA Vaccine to Treat Systemic Lupus Erythematosus in Mice

Interleukin-17 Expression Positively Correlates with Disease Severity of Lupus Nephritis by Increasing Anti-Double-stranded DNA Antibody Production in a Lupus Model Induced by Activated Lymphocyte Derived DNA.

Elevated Expression Of Transmembrane Il-15 In Immune Cells Correlates With The Development Of Murine Lupus: A Potential Target For Immunotherapy Against Sle

Induction of Systemic Lupus Erythematosus-Like Syndrome in Syngeneic Mice by Immunization with Activated Lymphocyte-Derived DNA

The DNA co-vaccination using Sm antigen and IL-10 as prophylactic experimental therapy ameliorates nephritis in a model of lupus induced by pristane

Interleukin-22 From Type 3 Innate Lymphoid Cells Aggravates Lupus Nephritis by Promoting Macrophage Infiltration in Lupus-Prone Mice

IL-17B alleviates the pathogenesis of systemic lupus erythematosus by inhibiting FASN-mediated differentiation of B cells

Effect of active immunization with IL-17A on B cell function and infection risk in pristane-induced lupus model

Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis

Induction of Systemic Lupus Erythematosus Syndrome in Balb/C Mice by Immunization with Active Chromatin

A Novel human IL‐23A Overexpressing Mouse Model of Systemic Lupus Erythematosus

[Eukaryotic Expression of Human IL17-RD-ECD and Generation of Its Monoclonal Antibody].

Anti‑IL‑39 (il‑23p19/ebi3) Polyclonal Antibodies Ameliorate Autoimmune Symptoms in Lupus‑like Mice

Induction and Characteristics of Systemic Lupus Erythematous Syndrome in Mice

Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway.

Increased Interleukin-22 Levels in Lupus Nephritis and Its Associated with Disease Severity: a Study in Both Patients and Lupus-Like Mice Model.

Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus

Amelioration of Lupus Nephritis by Serum Amyloid P Component Gene Therapy with Distinct Mechanisms Varied from Different Stage of the Disease

Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32)

Inhibition of miRNA associated with a disease-specific signature and secreted via extracellular vesicles of systemic lupus erythematosus patients suppresses target organ inflammation in a humanized mouse model

Early Treatment of Interleukin-33 can Attenuate Lupus Development in Young NZB/W F1 Mice